Company intelligence / Profile preview

Fagron

Rotterdam, Netherlandsfagron.com ↗

Ownership: Public · FAGR
Employees: ~4000
Development stage: Commercial

Overview

Fagron operates globally as a leader in pharmaceutical compounding and personalized medicine solutions. It supplies APIs and excipients for pharmacy compounding; develops innovative delivery vehicles; offers sterile/nonsterile outsourcing services; provides genomics-based diagnostic tools to guide therapy selection. The company serves over 300,000 customers worldwide including pharmacies, hospitals, clinics and prescribers across more than 30 countries. No clinical trial results are reported since it does not develop new drugs.

Therapeutic areas: Other
Modalities: Small moleculeBiologicDeviceGenomics services
Industry: Chemicals & Materials

Partnerships

Low Dose Naltrexone Research Trust collaborationGates Healthcare partnership via Fagron Academy for supporting US compounders

Financials

Market cap: $5.9M

Beyond the preview

Go deeper on Fagron.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fagron.

Explore the full profile